What top creators are saying about Eli Lilly and Company(LLY)— Page 3

New clinical data for Retatrutide shows superior weight loss and health markers, positioning it as a premium high-margin drug.

Described as a 'killer' stock due to dominance in the weight-loss drug market.

Primary benefactor of the peptide and GLP-1 weight-loss drug trend, currently trading at a slight discount.

GLP-1 drugs show significant clinical benefits for heart and brain health beyond weight loss, though risks like NAION should be monitored.

The popularity of GLP-1 drugs represents a massive market opportunity and a shift toward metabolic health abundance.

Applying AI to drug design, illustrating the 'Jevons Paradox' where efficiency in AI-driven research increases the overall demand for the resource.

Partnered with HIMS to provide access to its weight-loss drug Zepbound.

Resolved supply chain issues and is utilizing telehealth partners to capture extreme demand for its superior Tirzepatide product.

Dominating the cardiometabolic space with GLP-1 drugs and bypassing pharmacy friction through the LillyDirect DTC platform; developing 'triple-acting' molecules for 2025/2026.

The speaker is highly bullish on the massive expansion of the Total Addressable Market (TAM) for GLP-1s, citing applications in cardiovascular health, addiction, and chronic diseases beyond just weight loss.

A key player in the GLP-1 supply chain expected to benefit from the drug's expansion into non-obesity medical indications.

A primary public proxy for the rapidly growing GLP-1 and peptide market trend.

Bullish outlook due to the expansion of GLP-1 medications into broader chronic disease prevention and metabolic health.

Speculation regarding a potential future partnership with HIMS for peptide-related treatments.

Utilizing AI for massive data set analysis in clinical trials to improve profit margins.

Partnered with Insilico Medicine for AI-driven drug discovery which shows high clinical trial success rates.

Aggressively partnering with AI-first biotech firms like Insilico Medicine to collapse drug discovery timelines.

Key player in the GLP-1 market which is viewed as the entry point for reversing aging.

Leader in AI-driven drug discovery with a recent price reset providing a potential entry point.

Partnering with Amazon Pharmacy for same-day delivery of GLP-1 medications, leveraging Amazon's logistics network to capture the metabolic health market.

Partnership with Amazon Pharmacy for same-day delivery of new GLP-1 pill Foundayo provides a major growth lever.

Developing Retatrutide, a powerful upcoming triple agonist drug currently in Phase 3 trials.

Becoming a 'token factory' by using supercomputers and AI to revolutionize drug discovery.

As GLP-1 drugs gain social momentum, regulatory shifts may create moats for large pharmaceutical companies capable of navigating the clinical trial process.

Potential future distribution partnership with HIMS; competitor in the weight loss pill and peptide market.

Up 4% on news of a new oral weight-loss pill, Fondayo, expanding its market reach.

Showing positive momentum as a notable green performer.

Strategic $2.75 billion collaboration with Insilico Medicine to acquire AI-vetted drug candidates, potentially securing new GLP-1 assets.

Part of the 'health-maxing' and longevity investment theme involving peptides and weight loss.

Included in the curated model portfolio focusing on high-conviction hardware and infrastructure names.

Deeply integrated with the U.S. legislative process and highlighted as a major corporate donor to influential health committee members.

Dominant in weight-loss market with Zepbound; viewed as a long-term winner despite a recent 6% daily dip.

Positioned to benefit from regulatory crackdowns on unregulated peptides and the development of next-generation drugs like Retatrutide.

Potential future partnership with HIMS for retatrutide; HIMS has avoided competing with Lilly's tirzepatide.

Mentioned as a 'usual suspect' in political campaign contributions seeking to maintain Washington influence.

Holds a significant investment moat through patent protection on pharmaceutical chemistry; Retatrutide represents a high-potential next-generation metabolic treatment.

Identified as a primary tradable asset to capture the massive growth in the peptide and weight-loss market.

Collaborating with NVIDIA to utilize AI for drug discovery and R&D pipeline acceleration.

Viewed as brilliant for bypassing Pharmacy Benefit Managers (PBMs) to sell GLP-1 drugs directly to patients.

Positioned as a regulated heavyweight in the biopharmaceutical space with high-demand products like Retatrutide in trials.

Beneficiary of the 'Performance Medicine' trend among high-performers, specifically with its Retatrutide product.

Experiencing a massive revenue boom from next-generation peptides like Terzepatide and the upcoming Retatrutide catalyst.

Faces significant policy risk from federal and state-level price caps on insulin and potential competition from imported drugs.

Viewed as a more transformative investment than AI with significant upside due to health and addiction applications.

Remains a primary mover in the obesity drug market with Retatrutide showing subjects losing up to one-third of body weight in Phase 3 trials.

GLP-1 drugs are viewed as a more transformative economic force than AI, with massive potential to reduce healthcare costs.

Viewed as a potential 'Magnificent 7' member due to leadership in longevity and GLP-1 medications.

Developing Retatrutide, a potential 'game changer' drug that could disrupt the current Semaglutide market.

While facing pricing pressure, the company is actively onshoring manufacturing with six new plants in the U.S.

The normalization of weight loss drugs for non-diabetic use signals a strong bullish trend for the dominant market leaders.